A Specific IL6 Polymorphic Genotype Modulates the Risk of Trypanosoma cruzi Parasitemia While IL18, IL17A, and IL1B Variant Profiles and HIV Infection Protect Against Cardiomyopathy in Chagas Disease

Imagem de Miniatura
Arquivos
art_SANTOS_A_Specific_IL6_Polymorphic_Genotype_Modulates_the_Risk_2020.PDF.pdf (494.22 KB)
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
FERREIRA, Daiane Tomomi
NOVAES, Cristina Terra Gallafrio
Citação
FRONTIERS IN IMMUNOLOGY, v.11, article ID 521409, 15p, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Chagas disease caused by Trypanosoma cruzi (T. cruzi) affects approximately six million individuals worldwide. Clinical manifestations are expected to occur due to the parasite persistence and host immune response. Herein we investigated potential associations between IL1B, IL6, IL17A, or IL18 polymorphism profiles and cardiomyopathy or T. cruzi parasitemia, as well as the impact of HIV infection on cardiopathy. Methods Two hundred twenty-six patients and 90 control individuals were analyzed. IL1B rs1143627 T>C, IL6 rs1800795 C>G, IL17A rs2275913 G>A, IL18 rs187238 C>G, and IL18 rs1946518 C>A SNVs were analyzed by real-time PCR and T. cruzi parasitemia by PCR. Results Our data revealed association between a cytokine gene polymorphism and parasitemia never previously reported. The IL6 rs1800795 CG genotype lowered the risk of positive parasitemia (OR = 0.45, 95% CI 0.24-0.86, P = 0.015). Original findings included associations between IL17A rs2275913 AA and IL18 s1946518 AA genotypes with decreased risk of developing cardiomyopathy (OR = 0.27, 95% CI 0.07-0.97, P = 0.044; and OR = 0.35, 95% CI 0.14-0.87, P = 0.023, respectively). IL18 rs1946518 AA and IL1B rs1143627 TC were associated with reduced risk for cardiomyopathy severity, including NYHA (New York Heart Association) class >= 2 (OR = 0.21, 95% CI 0.06-0.68, P = 0.009; and OR = 0.48, 95% CI 0.24-0.95, P = 0.036, respectively) and LVEF (left ventricular ejection fraction) <45% for IL18 rs1946518 AA (OR = 0.22, 95% CI 0.05-0.89, P = 0.034). A novel, unexpected protective effect of HIV infection against development/progression of cardiomyopathy was identified, based on a lower risk of developing cardiopathy (OR = 0.48, 95% CI 0.23-0.96, P = 0.039), NYHA class >= 2 (OR = 0.15, 95% CI 0.06-0.39, P < 0.001), and LVEF < 45% (OR = 0.03, 95% CI 0.00-0.25, P = 0.001). Digestive involvement was negatively associated with NYHA >= 2 and LVEF < 45% (OR = 0.20, 95% CI 0.09-0.47, P < 0.001; and OR = 0.24, 95% CI 0.09-0.62, P = 0.004, respectively). Conclusions Our data support a protective role of IL17A AA, IL18 AA, and IL1B TC genotypes against development/progression of cardiomyopathy and a modulatory effect of the IL6 CG genotype on the risk of parasitemia in Chagas disease. Notably, HIV infection was shown to protect against development/progression of cardiopathy, potentially associated with a synergistic effect of HIV and highly active antiretroviral therapy (HAART), attenuating a Th1-mediated response in the myocardium. This proposed hypothesis requires confirmation, however, in larger and more comprehensive future studies.
Palavras-chave
T, cruzi parasitemia, cardiomyopathy, Chagas disease, HIV, IL1 B, IL6, IL17 A and IL18 polymorphisms
URI
https://observatorio.fm.usp.br/handle/OPI/38312
Referências
  1. Abel LCJ, 2001, J AUTOIMMUN, V17, P99, DOI 10.1006/jaut.2001.0523
  2. Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496
  3. Andreani G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008246
  4. Apt W, 2016, ACTA TROP, V162, P155, DOI 10.1016/j.actatropica.2016.06.025
  5. Balagopal A, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw118
  6. Barbaro G., 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P337, DOI 10.2174/1568006054553444
  7. Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
  8. Basquiera AL, 2003, HEART, V89, P1186, DOI 10.1136/heart.89.10.1186
  9. Bellera CL, 2015, EUR J MED CHEM, V93, P338, DOI 10.1016/j.ejmech.2015.01.065
  10. Bennett JA, 2002, HEART LUNG, V31, P262, DOI 10.1067/mhl.2002.124554
  11. Benvenuti LA, 2008, ANN TROP MED PARASIT, V102, P481, DOI 10.1179/136485908X311740
  12. Bocchi EA, 2017, J AM COLL CARDIOL, V70, P1510, DOI 10.1016/j.jacc.2017.08.004
  13. Borges DC, 2013, IMMUNOLOGY, V138, P145, DOI 10.1111/imm.12022
  14. BRITTO C, 1993, MEM I OSWALDO CRUZ, V88, P171, DOI 10.1590/S0074-02761993000100030
  15. Buschenfelde CMZ, 1997, CLIN EXP IMMUNOL, V110, P378, DOI 10.1046/J.1365-2249.1997.4471463.X
  16. Cai CW, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005902
  17. Castilho Vanessa V S, 2018, BMC Res Notes, V11, P825, DOI 10.1186/s13104-018-3927-z
  18. Chandrasekar B, 1998, AM J PATHOL, V152, P925
  19. Chandrasekar B, 2005, J BIOL CHEM, V280, P4553, DOI 10.1074/jbc.M411787200
  20. Chen DY, 2009, LUPUS, V18, P29, DOI 10.1177/0961203308094559
  21. Chien Y, 2016, ONCOTARGET, V7, P87161, DOI 10.18632/oncotarget.13552
  22. Collins LM, 2001, PSYCHOL METHODS, V6, P330, DOI 10.1037//1082-989X.6.4.330
  23. Correa JD, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/846052
  24. D'Avila DA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208133
  25. Guedes PMD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000604
  26. de Araujo FF, 2012, IMMUNOBIOLOGY, V217, P768, DOI 10.1016/j.imbio.2012.04.008
  27. Dutra WO, 2008, CURR OPIN INFECT DIS, V21, P287, DOI 10.1097/QCO.0b013e3282f88b80
  28. Dziedziejko V, 2012, POSTEP HIG MED DOSW, V66, P409, DOI 10.5604/17322693.1000980
  29. El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081
  30. Erdmann H, 2013, IMMUNOBIOLOGY, V218, P910, DOI 10.1016/j.imbio.2012.10.005
  31. Eslick GD, 2009, INT J CARDIOL, V137, P81, DOI 10.1016/j.ijcard.2008.05.017
  32. Esper L, 2014, MICROBES INFECT, V16, P481, DOI 10.1016/j.micinf.2014.03.007
  33. Espinoza JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026229
  34. Fae KC, 2000, MICROBES INFECT, V2, P745, DOI 10.1016/S1286-4579(00)00501-3
  35. Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629
  36. Florez O, 2006, HUM IMMUNOL, V67, P741, DOI 10.1016/j.humimm.2006.06.004
  37. Furucho CR, 2008, TROP MED INT HEALTH, V13, P1527, DOI 10.1111/j.1365-3156.2008.02172.x
  38. Gao WD, 2002, INT J PARASITOL, V32, P167, DOI 10.1016/S0020-7519(01)00322-8
  39. Giannitrapani L, 2011, OMICS, V15, P183, DOI 10.1089/omi.2010.0093
  40. Giedraitis V, 2001, J NEUROIMMUNOL, V112, P146, DOI 10.1016/S0165-5728(00)00407-0
  41. GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
  42. Hall SK, 2004, ARTHRITIS RHEUM-US, V50, P1976, DOI 10.1002/art.20310
  43. Hasan F, 2017, J INFECT DIS MED, V2, P117
  44. Iannello A, 2010, J INFECT DIS, V201, P608, DOI 10.1086/650314
  45. Jurecekova J, 2017, NEOPLASMA, V64, P148, DOI 10.4149/neo_2017_119
  46. Keating SM, 2015, INT J CARDIOL, V199, P451, DOI 10.1016/j.ijcard.2015.07.040
  47. Kim SW, 2011, GUT, V60, P1527, DOI 10.1136/gut.2011.238477
  48. Rodriguez DAL, 2015, GENES IMMUN, V16, P536, DOI 10.1038/gene.2015.42
  49. Rodriguez DAL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004583
  50. Nascimento MSL, 2015, J INFECT DIS, V211, P1015, DOI 10.1093/infdis/jiu531
  51. Lopez L, 2006, REV ESP CARDIOL, V59, P50, DOI 10.1157/13083649
  52. Lorente L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111861
  53. Luft T, 2002, J IMMUNOL, V168, P713, DOI 10.4049/jimmunol.168.2.713
  54. Magalhaes LMD, 2013, J INFECT DIS, V207, P661, DOI 10.1093/infdis/jis724
  55. Matos CS, 2014, MEM I OSWALDO CRUZ, V109, P374, DOI 10.1590/0074-0276130385
  56. Guedes PMM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001630
  57. Miyazaki Y, 2010, J IMMUNOL, V185, P1150, DOI 10.4049/jimmunol.0900047
  58. Muller U, 2001, J IMMUNOL, V167, P3346, DOI 10.4049/jimmunol.167.6.3346
  59. Nogueira LG, 2015, CYTOKINE, V73, P79, DOI 10.1016/j.cyto.2015.01.037
  60. Nogueira LG, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/914326
  61. Norman FF, 2011, ANN TROP MED PARASIT, V105, P425, DOI 10.1179/1364859411Y.0000000033
  62. O'Brien LC, 2014, MOL MED, V20, P221, DOI 10.2119/molmed.2014.00034
  63. Okuhara Y, 2017, INT J CARDIOL, V243, P396, DOI 10.1016/j.ijcard.2017.04.082
  64. Petersen CA, 2003, INFECT IMMUN, V71, P4441, DOI 10.1128/IAI.71.8.4441-4447.2003
  65. Dias JCP, 2016, REV SOC BRAS MED TRO, V49, P3, DOI 10.1590/0037-8682-0505-2016
  66. Pitta MGR, 2009, J CLIN INVEST, V119, P2379, DOI 10.1172/JCI38813
  67. Rassi A, 2006, NEW ENGL J MED, V355, P799, DOI 10.1056/NEJMoa053241
  68. Reddy VS, 2008, J CELL PHYSIOL, V215, P697, DOI 10.1002/jcp.21348
  69. Reis MM, 1997, CLIN IMMUNOL IMMUNOP, V83, P165, DOI 10.1006/clin.1997.4335
  70. Reis PG, 2017, J IMMUNOL RES, V2017, P7, DOI 10.1155/2017/1017621
  71. Rodrigues DBR, 2005, REV SOC BRAS MED TRO, V38, P483, DOI 10.1590/S0037-86822005000600007
  72. Sabino EC, 2015, EUR J HEART FAIL, V17, P416, DOI 10.1002/ejhf.220
  73. Sakai K, 2008, J INFECT DIS, V197, P1752, DOI 10.1086/588196
  74. Samarani S, 2016, CYTOKINE, V82, P38, DOI 10.1016/j.cyto.2016.01.006
  75. Sanchez E, 2009, HUM MOL GENET, V18, P3739, DOI 10.1093/hmg/ddp301
  76. Sangenito LS, 2018, INT J ANTIMICROB AG, V52, P185, DOI 10.1016/j.ijantimicag.2018.03.021
  77. Sangenito LS, 2016, INT J ANTIMICROB AG, V48, P703, DOI 10.1016/j.ijantimicag.2016.09.017
  78. Sangenito LS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113957
  79. Sanmarco LM, 2017, BBA-MOL BASIS DIS, V1863, P857, DOI 10.1016/j.bbadis.2017.01.006
  80. Sartori AMC, 2007, ANN TROP MED PARASIT, V101, P31, DOI 10.1179/136485907X154629
  81. Sedaghat AR, 2009, CLIN INFECT DIS, V49, P1763, DOI 10.1086/648081
  82. SILVA JS, 1993, AM J TROP MED HYG, V49, P589, DOI 10.4269/ajtmh.1993.49.589
  83. Sousa GR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172833
  84. Sousa GR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087082
  85. Strauss M, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007859
  86. Talar-Wojnarowska R, 2009, DIGEST DIS SCI, V54, P683, DOI 10.1007/s10620-008-0390-z
  87. de Freitas VLT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001277
  88. Torres OA, 2010, TISSUE ANTIGENS, V76, P131, DOI 10.1111/j.1399-0039.2010.01478.x
  89. Xiao H, 2018, EUR HEART J, V39, P60, DOI 10.1093/eurheartj/ehx261
  90. Zhang L, 1999, J INFECT DIS, V180, P480, DOI 10.1086/314889
  91. Zidan HE, 2015, IMMUNOGENETICS, V67, P665, DOI 10.1007/s00251-015-0876-8
  92. Zingales B, 2012, INFECT GENET EVOL, V12, P240, DOI 10.1016/j.meegid.2011.12.009

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Carregar mais